ClinicalTrials.gg
CompletedNCT01570751Updated Mar 7, 2017Results posted

A Trial Comparing the Efficacy, Patient-reported Outcomes and Safety of Insulin Degludec 200 U/mL vs Insulin Glargine in Subjects With Type 2 Diabetes Mellitus Requiring High-dose Insulin

A Phase 3 interventional study of insulin degludec and insulin glargine in Diabetes and Diabetes Mellitus, Type 2, sponsored by Novo Nordisk A/S. Completed at 46 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-03-07.

Primary conditionDiabetes Mellitus, Type 2Registry: Diabetes MellitusReclassifiedWhy we changed it
Registry
Diabetes Mellitus — the first condition term the registry derived for this study.
ClinicalTrials.gg
Diabetes Mellitus, Type 2
Why
  1. The study's listed conditions name Diabetes Mellitus, Type 2, a narrower term within Diabetes Mellitus.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
145
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 70 studies testing insulin degludec in Diabetes Mellitus, Type 2 — 4 open to participants now, 4 under way, 2 of them phase 3. insulin degludec · Diabetes Mellitus, Type 2.

Enrollment
52nd of 70
145 · median 384
Started
2012
with 5 others
Phase 3
49 of 70
2 open now
Registered
27th of 70
by date
Lead sponsor
56 of 70
Novo Nordisk A/S

Among the 70 studies testing insulin degludec in Diabetes Mellitus, Type 2, this one is the 52nd largest by enrollment, is one of 6 that started in 2012, is one of 49 in phase 3, and was the 27th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

4 of the 70 studies testing insulin degludec in Diabetes Mellitus, Type 2 are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About insulin degludec

insulin degludec: first FDA approval 2015 (RYZODEG 70/30), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 70 studies testing insulin degludec in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

This trial is conducted in the United States of America (USA). The aim of the trial is to confirm the efficacy of IDeg (insulin degludec) versus IGlar (insulin glargine) in controlling glycaemia. Subjects are to continue their pre-trial metformin treatment.

03

Conditions studied

  • Diabetes
  • Diabetes Mellitus, Type 2

Browse trials for

04

In context

Diabetes Mellitus, Type 2 Reclassified

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

This study's enrollment of 145 is above the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.

Browse Diabetes Mellitus, Type 2 studies →

Lead sponsor

Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.

Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.

Compared within Diabetes Mellitus, Type 2, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Type 2 diabetes
  • Current treatment with once daily insulin glargine in vials with a daily dose equal to or above 65 U and equal to or below 100 U
  • Current treatment with a stable dose of metformin plus/minus one additional oral antidiabetic drug (OAD) for at least 12 weeks
  • Glycosylated () equal to or above 7.5%

Exclusion criteria

Exclusion Criteria:

  • Current treatment with insulin other than insulin glargine in vials
  • Treatment with thiazolidinediones or glucagon-like peptide-1 (GLP-1) receptor agonists within 12 weeks
  • Stroke; heart failure; myocardial infarction; unstable angina pectoris; coronary arterial bypass graft or angioplasty
  • Suffer from cancer (except basal cell skin cancer and squamous-cell cancer)
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
145 participants (actual)

Study arms

  • Experimental
    IDeg followed by IGlar

    Drug: insulin degludec · Drug: insulin glargine

  • Experimental
    IGlar followed by IDeg

    Drug: insulin degludec · Drug: insulin glargine

Interventions

  • Cross-over trial, part 1: Individually adjusted IDeg administered subcutaneously (s.c., under the skin) once daily for 16 weeks in each treatment period.

  • Cross-over trial, part 2: Individually adjusted IGlar administered subcutaneously (s.c., under the skin) once daily for the 16 week run-in period followed by 16 weeks in each treatment period.

07

What researchers measure

Primary outcomes

  1. Change From Baseline (Visit 18) in Glycosylated Haemoglobin (HbA1c) at the End of Each 16 Week Treatment Period

    Values for change in HbA1c after each 16 weeks of treatment periods A and B.

    Time frame: Week 0, week 16 of each treatment period.

Secondary outcomes

  1. Change in Patient Reported Outcome (PRO) Scores From Baseline to the End of Each 16 Week Treatment Period

    Changes in subjects quality of life and insulin device satisfaction were evaluated using the following PROs: the Short-Form 36 Health Survey version 2 (SF-36) and the Treatment Related Impact Measure-Diabetes Device (TRIM-DD). PRO total scores were measured from baseline to the end of each 16-week treatment period. Responses were measured on a scale of 0 to 100, where higher scores indicated a better quality of life and higher insulin device satisfaction on the SF-36 and TRIM-DD questionnaires, respectively.

    Time frame: Week 0, week 16 of each treatment period.

  2. Change in PRO Scores From the End of Treatment Period A Until After 4 Weeks of Treatment in Treatment Period B

    SF-36 and TRIM-DD total scores were measured at the end of treatment A (week 16) and 4 weeks into treatment B (week 20). Responses were measured on a scale of 0 to 100, where higher scores indicated a better quality of life and higher insulin device satisfaction on the SF-36 and TRIM-DD questionnaires, respectively.

    Time frame: Week 16, week 20

  3. Change From Baseline in Central Laboratory Measured Fasting Plasma Glucose (FPG) at the End of Each 16 Week Treatment Period

    Values of FPG in mmol/L from baseline to each 16 weeks of treatment periods.

    Time frame: Week 0, week 16, week 32

  4. Change in FPG From the End of Treatment Period A Until After 4 Weeks of Treatment in Treatment Period B

    Values of FPG in mmol/L from the end of treatment period A until after 4 weeks of treatment in treatment period B.

    Time frame: Week 16, week 20

  5. Number of Adverse Events (AEs)

    Number of treatment emergent adverse events (TEAEs) from week 0 to week 16 of the randomised treatment periods. A TEAE was defined as an event that had onset date on or after the first day of exposure to randomised treatment and no later than 7 days after the last day of randomised treatment. TEAEs were attributed to the treatment given in the period in which the event occurred.

    Time frame: From baseline to the end of each 16 week treatment period.

08

Results

Posted Nov 18, 2015

Participant flow

The trial was conducted at 37 sites in the United States of America (USA).

Period A (16 Weeks)
Participant flow — Period A (16 Weeks)
MilestoneIDeg/IGlarIGlar/IDeg
Started7372
Exposed7372
Completed7067
Not completed35
Withdrew: Protocol violation11
Withdrew: Withdrawal criteria01
Withdrew: Unclassified23
Period B (16 Weeks)
Participant flow — Period B (16 Weeks)
MilestoneIDeg/IGlarIGlar/IDeg
Started7067
Exposed7067
Completed6966
Not completed11
Withdrew: Adverse event10
Withdrew: Protocol violation01

Outcome measures

PrimaryChange From Baseline (Visit 18) in Glycosylated Haemoglobin (HbA1c) at the End of Each 16 Week Treatment Period

Values for change in HbA1c after each 16 weeks of treatment periods A and B.

Time frame:
Week 0, week 16 of each treatment period.
Reported as:
Mean · percentage of glycosylated haemoglobin
Change From Baseline (Visit 18) in Glycosylated Haemoglobin (HbA1c) at the End of Each 16 Week Treatment Period
percentage of glycosylated haemoglobinIDegIGlar
Change From Baseline (Visit 18) in Glycosylated Haemoglobin (HbA1c) at the End of Each 16 Week Treatment Period-0.1 ± 1.1-0.1 ± 1.1
SecondaryChange in Patient Reported Outcome (PRO) Scores From Baseline to the End of Each 16 Week Treatment Period

Changes in subjects quality of life and insulin device satisfaction were evaluated using the following PROs: the Short-Form 36 Health Survey version 2 (SF-36) and the Treatment Related Impact Measure-Diabetes Device (TRIM-DD). PRO total scores were measured from baseline to the end of each 16-week treatment period. Responses were measured on a scale of 0 to 100, where higher scores indicated a better quality of life and higher insulin device satisfaction on the SF-36 and TRIM-DD questionnaires, respectively.

Time frame:
Week 0, week 16 of each treatment period.
Reported as:
Mean · scores on a scale
Change in Patient Reported Outcome (PRO) Scores From Baseline to the End of Each 16 Week Treatment Period
scores on a scaleIDegIGlar
Physical score-0.8 ± 7.7-0.6 ± 7.8
Mental score0.7 ± 9.30.4 ± 10.4
Total D-device11.0 ± 19.13.5 ± 19.1
SecondaryChange in PRO Scores From the End of Treatment Period A Until After 4 Weeks of Treatment in Treatment Period B

SF-36 and TRIM-DD total scores were measured at the end of treatment A (week 16) and 4 weeks into treatment B (week 20). Responses were measured on a scale of 0 to 100, where higher scores indicated a better quality of life and higher insulin device satisfaction on the SF-36 and TRIM-DD questionnaires, respectively.

Time frame:
Week 16, week 20
Reported as:
Mean · scores on a scale
Change in PRO Scores From the End of Treatment Period A Until After 4 Weeks of Treatment in Treatment Period B
scores on a scaleIDeg/IGlarIGlar/IDeg
Physical score0.02 ± 7.070.60 ± 6.09
Mental score0.61 ± 8.880.21 ± 8.59
Total D-device10.24 ± 19.89-6.25 ± 11.10
SecondaryChange From Baseline in Central Laboratory Measured Fasting Plasma Glucose (FPG) at the End of Each 16 Week Treatment Period

Values of FPG in mmol/L from baseline to each 16 weeks of treatment periods.

Time frame:
Week 0, week 16, week 32
Reported as:
Mean · mmol/L
Change From Baseline in Central Laboratory Measured Fasting Plasma Glucose (FPG) at the End of Each 16 Week Treatment Period
mmol/LIDegIGlar
Change From Baseline in Central Laboratory Measured Fasting Plasma Glucose (FPG) at the End of Each 16 Week Treatment Period-0.8 ± 4.2-0.0 ± 4.4
SecondaryChange in FPG From the End of Treatment Period A Until After 4 Weeks of Treatment in Treatment Period B

Values of FPG in mmol/L from the end of treatment period A until after 4 weeks of treatment in treatment period B.

Time frame:
Week 16, week 20
Reported as:
Mean · mmol/L
Change in FPG From the End of Treatment Period A Until After 4 Weeks of Treatment in Treatment Period B
mmol/LIDeg/IGlarIGlar/IDeg
Change in FPG From the End of Treatment Period A Until After 4 Weeks of Treatment in Treatment Period B-0.78 ± 3.410.19 ± 4.40
SecondaryNumber of Adverse Events (AEs)

Number of treatment emergent adverse events (TEAEs) from week 0 to week 16 of the randomised treatment periods. A TEAE was defined as an event that had onset date on or after the first day of exposure to randomised treatment and no later than 7 days after the last day of randomised treatment. TEAEs were attributed to the treatment given in the period in which the event occurred.

Time frame:
From baseline to the end of each 16 week treatment period.
Reported as:
Number · events
Number of Adverse Events (AEs)
eventsIDegIGlar
Number of Adverse Events (AEs)105111

Adverse events

Collected over The adverse events were collected in a time frame of 32 weeks + 7 days follow up. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
IDeg—4/140 (2.9%)2/140 (1.4%)
IGlar—4/142 (2.8%)9/142 (6.3%)
Most frequent serious events
Most frequent serious events
EventIDegIGlar
Angina unstableCardiac disorders1/1400/142
MastoiditisInfections and infestations1/1400/142
HypoglycaemiaMetabolism and nutrition disorders1/1400/142
Cervical spinal stenosisMusculoskeletal and connective tissue disorders1/1400/142
Acute coronary syndromeCardiac disorders0/1401/142
Urinary tract infectionInfections and infestations0/1401/142
Back painMusculoskeletal and connective tissue disorders0/1401/142
EpididymitisReproductive system and breast disorders0/1401/142
Pulmonary embolismRespiratory, thoracic and mediastinal disorders0/1401/142
Most frequent other events
Most frequent other events
EventIDegIGlar
NasopharyngitisInfections and infestations2/1409/142

Baseline characteristics

For 4 subjects baseline fasting plasma glucose (FPG) values were missing, hence did not contribute to the FPG summary.

Age, Continuous
Age, Continuous(years)IDeg/IGlarIGlar/IDegTotal
Mean54.7 ± 10.255.8 ± 9.055.3 ± 9.6
Sex: Female, Male
Sex: Female, Male(Participants)IDeg/IGlarIGlar/IDegTotal
Female312455
Male424890
Glycosylated haemoglobin (HbA1c)
Glycosylated haemoglobin (HbA1c)(percentage of glycosylated haemoglobin)IDeg/IGlarIGlar/IDegTotal
Mean8.0 ± 1.18.3 ± 1.48.2 ± 1.3
Fasting plasma glucose (FPG)
Fasting plasma glucose (FPG)(mmol/L)IDeg/IGlarIGlar/IDegTotal
Mean7.5 ± 3.38.5 ± 4.18.0 ± 3.7
09

Study locations

46 sites
  • Novo Nordisk Investigational Site
    Mesa, Arizona 85206, United States
  • Novo Nordisk Investigational Site
    Fresno, California 93720, United States
  • Novo Nordisk Investigational Site
    Greenbrae, California 94904, United States
  • Novo Nordisk Investigational Site
    San Ramon, California 94583, United States
  • Novo Nordisk Investigational Site
    Bradenton, Florida 34201, United States
  • Novo Nordisk Investigational Site
    Hialeah, Florida 33012, United States
  • Novo Nordisk Investigational Site
    Homestead, Florida 33030, United States
  • Novo Nordisk Investigational Site
    Jacksonville, Florida 32207, United States
  • Novo Nordisk Investigational Site
    Kissimmee, Florida 34741, United States
  • Novo Nordisk Investigational Site
    Miami Lakes, Florida 33016, United States
  • Novo Nordisk Investigational Site
    Miami, Florida 33155, United States
  • Novo Nordisk Investigational Site
    Miami, Florida 33156, United States
  • Novo Nordisk Investigational Site
    St. Petersburg, Florida 33709, United States
  • Novo Nordisk Investigational Site
    Roswell, Georgia 30076, United States
  • Novo Nordisk Investigational Site
    Avon, Illinois 46123, United States
  • Novo Nordisk Investigational Site
    Chicago, Illinois 60611, United States
  • Novo Nordisk Investigational Site
    Lexington, Kentucky 40502, United States
  • Novo Nordisk Investigational Site
    Madisonville, Kentucky 42431, United States
  • Novo Nordisk Investigational Site
    Metairie, Louisiana 70002, United States
  • Novo Nordisk Investigational Site
    Slidell, Louisiana 70461-4231, United States
  • Novo Nordisk Investigational Site
    Rockville, Maryland 20852, United States
  • Novo Nordisk Investigational Site
    Worcester, Massachusetts 01655, United States
  • Novo Nordisk Investigational Site
    Southfield, Michigan 48034-7661, United States
  • Novo Nordisk Investigational Site
    Jefferson City, Missouri 65109, United States
  • Novo Nordisk Investigational Site
    Las Vegas, Nevada 89106, United States
  • Novo Nordisk Investigational Site
    Lawrenceville, New Jersey 08648, United States
  • Novo Nordisk Investigational Site
    Albany, New York 12206, United States
  • Novo Nordisk Investigational Site
    Northport, New York 11768, United States
  • Novo Nordisk Investigational Site
    Staten Island, New York 10301, United States
  • Novo Nordisk Investigational Site
    Greenville, North Carolina 27834, United States
  • Novo Nordisk Investigational Site
    Franklin, Ohio 45005, United States
  • Novo Nordisk Investigational Site
    Kettering, Ohio 45429, United States
  • Novo Nordisk Investigational Site
    Philadelphia, Pennsylvania 19107, United States
  • Novo Nordisk Investigational Site
    Chattanooga, Tennessee 37411, United States
  • Novo Nordisk Investigational Site
    Kingsport, Tennessee 37660, United States
  • Novo Nordisk Investigational Site
    Nashville, Tennessee 37212, United States
  • Novo Nordisk Investigational Site
    Dallas, Texas 75218, United States
  • Novo Nordisk Investigational Site
    Dallas, Texas 75230, United States
  • Novo Nordisk Investigational Site
    Dallas, Texas 75246, United States
  • Novo Nordisk Investigational Site
    Kingsville, Texas 78363-6322, United States
  • Novo Nordisk Investigational Site
    San Antonio, Texas 78207, United States
  • Novo Nordisk Investigational Site
    Schertz, Texas 78154, United States
  • Novo Nordisk Investigational Site
    Sugar Land, Texas 77478, United States
  • Novo Nordisk Investigational Site
    Tacoma, Washington 98405, United States
  • Novo Nordisk Investigational Site
    Milwaukee, Wisconsin 53209, United States
  • Novo Nordisk Investigational Site
    Manati, 00674, Puerto Rico
10

References and documents

Publications

  • Warren ML, Chaykin LB, Jabbour S, Sheikh-Ali M, Hansen CT, Nielsen TSS, Norwood P. Insulin Degludec 200 Units/mL Is Associated With Lower Injection Frequency and Improved Patient-Reported Outcomes Compared With Insulin Glargine 100 Units/mL in Patients With Type 2 Diabetes Requiring High-Dose Insulin. Clin Diabetes. 2017 Apr;35(2):90-95. doi: 10.2337/cd15-0058. PubMed 28442823 ↗
  • Warren ML, Brod M, Hakan-Bloch J, Sparre T, Chaykin LB. Patient-reported outcomes from a randomized, crossover trial comparing a pen injector with insulin degludec versus a pen injector with insulin glargine U100 in patients with type 2 diabetes. Curr Med Res Opin. 2019 Sep;35(9):1623-1629. doi: 10.1080/03007995.2019.1605769. Epub 2019 May 21. PubMed 30974973 ↗
11

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2012, a primary completion of Jan 2014 and a completion of Jan 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2015, 1 year 10 months after primary completion. A results delay was requested in Jan 2014.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 2, 2012
First posted
Apr 4, 2012
Start
Apr 2012
Primary completionActual
Jan 2014
CompletionActual
Jan 2014
Results delay requested
Jan 24, 2014
Results first posted
Nov 18, 2015
Last update
Mar 7, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 7, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT01570751
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Apr 4, 2012
Start date
Apr 2012
Primary completion
Jan 2014
Completion
Jan 2014
Results posted
Nov 18, 2015
Last update
Mar 7, 2017

Study contacts

Global Clinical Registry (GCR, 1452)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Insulin degludec · Insulin Glargine

Start the discussion